Cutaneous Adverse Events Following Nemolizumab Administration: A Review

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 3026 - 3026

Published: April 27, 2025

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction and immune dysregulation, with interleukin (IL)-4, IL-13, IL-31 recognized as key mediators. Prurigo nodularis (PN) another disorder driven T helper type 2-mediated inflammation neural leading to severe pruritus. Nemolizumab, humanized monoclonal antibody targeting receptor A, has been approved for use in the treatment of AD PN. Clinical trials have demonstrated significant reductions pruritus cutaneous symptoms associated its use. In clinical practice, acute eczema edematous erythema frequently occur, occasionally necessitating discontinuation treatment. Despite these observations, no comprehensive review examined nemolizumab-associated adverse events. This aimed examine various reactions nemolizumab therapy, including psoriasiform eruptions, exacerbation, bullous pemphigoid, drug-induced fungal infections. Potential mechanisms underlying include T-cell activation due drug sensitization, responses triggered acting hapten, relative increase IL-4 IL-13 levels following inhibition. However, precise pathophysiological mechanism risk factors remain unclear, standardized management guidelines are lacking. Further accumulation data immunological research essential developing evidence-based strategies manage events, ensuring continuity optimizing patient outcomes.

Language: Английский

---

Current Status of Prurigo Nodularis in Japan: A Retrospective Study Using a Health Insurance Claims Database

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1872 - 1872

Published: March 11, 2025

Background/Objectives: Prurigo nodularis (PN) is associated with considerable disease burden. Limited information exists about the epidemiology, treatment patterns, and impact of PN. This retrospective study used Japanese health insurance claims data to investigate prevalence incidence PN from 2006 2021. Methods: A cross-sectional design was estimate longitudinally; a cohort assess comorbidities, healthcare resource utilization (HCRU). Results: Over period, 297,545 10,081,414 individuals were available annually; in 2020, 1946 diagnosed The showed little variation over period; 2021, 41 per 100,000 persons. Although there tendency for higher childhood, similar other age groups slightly females. Inflammatory skin diseases atopic diathesis common comorbidities. most prescribed treatments adults topical steroids (78%), oral antihistamines (68%), moisturizers (54%). Oral steroids, macrolides, psychotropics >10% patients. Individuals who also had dermatitis (AD) received cumulative doses stronger potency local steroid injections, than those without concomitant AD. Additionally, HCRU Conclusions: patients are usually treated according guidelines, an unmet need more effective due frequent use intensive late-line treatments.

Language: Английский

---

Functional Magnetic Resonance Imaging in Prurigo Nodularis: A Systematic Review

Clinics in Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1886 - 1886

Published: Aug. 19, 2024

Immune checkpoints are mechanisms that allow cancer cells to evade immune surveillance and avoid destruction by the body's system. Tumor exploit checkpoint proteins inhibit T cell activation, thus enhancing their resistance attacks. inhibitors, like nivolumab, work reactivating these suppressed target cells. However, this reactivation can disrupt balance cause immune-related adverse events. This report presents a rare case of prurigo nodularis developed six months after administering nivolumab for lung adenocarcinoma. While events commonly linked helper-1- or helper-17-type inflammations, helper-2-type inflammatory reactions, as observed in our case, unusual. The PD-1-PD-L1 pathway is typically associated with helper-1 17 responses, whereas PD-1-PD-L2 helper-2 responses. Inhibition PD-1 enhance PD-L1 functions, potentially shifting response towards types, but it may also influence inflammation. study reviews diseases emerging from inhibitor treatment, highlighting novelty findings.

Language: Английский

---

Dupilumab may break the “itch‐scratch cycle” in chronic prurigo and induce remission in a subset of patients

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 9, 2024

The data that support the findings of this study are available from corresponding author upon reasonable request.

Language: Английский

---